• About
  • Partnerships
  • Challenges
  • Awards
  • Grant Opportunities
  • News

Bacteriophage Particles to Target the Intestinal Microbiome

Todd Parsley of SynPhaGen, LLC in the U.S. will engineer phage-like particles to transfer genes into specific bacteria in the infant gut that program them to produce therapeutic proteins that protect against environmental enteric dysfunction, which is a major cause of morbidity and mortality in developing countries. Rather than employing bacteria-infecting phage to destroy bacteria, they will engineer safer particles, which are unable to replicate and do not kill the bacterial host. As proof-of-principle, they will modify the defective bacteriophage particles to carry a gene encoding the protein alkaline phosphatase, which keeps the gut healthy in multiple ways including neutralizing bacterial toxins, and program them to infect the bacterium Bacteriodes thetaiotaomicron. The activity of these particles will then be assessed in a mouse model of environmental enteric dysfunction.

More information about Addressing Newborn and Infant Gut Health Through Bacteriophage-Mediated Microbiome Engineering (Round 16)

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit www.grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.